Beta-Nicotinamide Mononucleotide (NMN) Market Size, Share, Growth, And Industry Analysis, By Type (Content Greater than or Equal to 98% and Content Less than 98%), By Application (Health Care Products, Cosmetics and Others), Regional Forecast To 2033

• 

  Request a Free sample to learn more about this report

BETA-NICOTINAMIDE MONONUCLEOTIDE (NMN) MARKET OVERVIEW

The global beta-nicotinamide mononucleotide (nmn) market was valued at USD 0.51 billion in 2024 and is expected to grow to USD 0.61 billion in 2025, reaching USD 2.69 billion by 2033, with a projected CAGR of 20.2% during the forecast period.

The formation of the coenzyme nicotinamide adenine dinucleotide (NAD+), which is essential for many biological functions such as energy metabolism and DNA repair, begins with the molecule nicotinamide mononucleotide (NMN). As we get older, our body's NAD+ levels decline, which is thought to speed up ageing and cause age-related disorders. A sequence of chemical processes transforms NMN, which is a precursor to NAD+, into NAD+. The most bioavailable and efficient form of NMN for increasing NAD+ levels is thought to be beta-nicotinamide mononucleotide (-NMN). NAD+ levels have been found to rise in a variety of tissues and organs, including the brain, liver, and muscle, when NMN or -NMN is supplemented.  

BETA-NICOTINAMIDE MONONUCLEOTIDE (NMN) MARKET KEY FINDINGS

COVID-19 IMPACT

Pandemic Hamper the Demand of Beta-Nicotinamide Mononucleotide (NMN) to Market Growth 

NMN may have potential benefits in supporting the immune system and reducing inflammation, which could be beneficial in the context of COVID-19. NAD+ levels have been shown to decrease with age and in various chronic diseases, including viral infections, and this may contribute to impaired immune function. NMN supplementation has been found to increase NAD+ levels and improve immune functions. One study found that NMN administration in aged mice improved their immune function and reduced the severity of influenza infection. 

LATEST TRENDS

NMN is the Growing Quantity of Studies and Clinical Trials Research to Support Market Expansion

The most recent development in NMN research is the rise in clinical trials and studies looking at its possible advantages. An increasing body of research suggests that NMN may also improve metabolic health, enhance cardiovascular health, and reduce inflammation in addition to its anti-aging properties. Several clinical experiments are now being conducted to investigate the security and effectiveness of NMN supplementation in humans.

• Functional‑food approval in Japan: In late 2024, the Japanese Ministry of Health officially approved NMN as a functional food ingredient, marking a watershed moment—over 7.2 million Japanese now regularly consume NMN capsules or powders, per Japan’s Ministry of Health data

• Surge in product launches: According to the Global Info Research association, over 600 new NMN‐based products hit the global market in 2023, a 28% year‑on‑year increase

Request a Free sample to learn more about this report

BETA-NICOTINAMIDE MONONUCLEOTIDE (NMN) MARKET SEGMENTATION

By Type Analysis

According to type, the beta-nicotinamide mononucleotide (NMN) market can be segmented content greater than or equal to 98% and content less than 98%.  

In terms of type, the content greater than or equal to 98% is anticipated to be the largest segment during the forecast period.  

By Application Analysis

Based on application, the beta-nicotinamide mononucleotide (NMN) market can be divided into health care products, cosmetics, and others.

In terms of application, the health care products market is projected to hold the largest beta-nicotinamide mononucleotide (NMN) market share through 2033.  

DRIVING FACTORS

Anti-Aging Properties Improvements in Physical will Drive Market Growth

One of the primary driving factors behind the increased interest in Beta-Nicotinamide Mononucleotide (NMN) is its potential as an anti-aging supplement. NMN has been shown to increase NAD+ levels in various tissues and organs, leading to improvements in physical and cognitive function, as well as potential reductions in age-related diseases. 

• User base of adults aged 50+: In the U.S., more than 40% of NMN product users are aged 45 and above—a strong signal of demand from middle‑aged and older demographics

• Robust clinical pipeline: Over 75 human clinical trials on NMN are currently ongoing or completed globally, according to the NMN Clinical Trials Consortium, bolstering consumer confidence

Clinical Trials and Research on Anti-Aging Techniques Will Help the Market Flourish

The increasing number of studies and clinical trials investigating the potential benefits of NMN is driving interest in this supplement. There is growing evidence that NMN may have a range of potential benefits, including metabolic health, cardiovascular health, and reducing inflammation. The availability of NMN supplements has increased in recent years, with many companies now offering NMN supplements in various forms, including capsules, powders, and sublingual tablets. This has made it easier for individuals to access and try this supplement.  

RESTRAINING FACTORS

Inadequate Regulation and a Lack of Long-Term Safety Data Will Impede Market Growth

While beta-nicotinamide mononucleotide (NMN) has been shown to be generally safe in animal studies and short-term human trials, there is a lack of long-term safety data. This has raised concerns about potential side effects and the safety of using NMN supplements or beta-nicotinamide mononucleotide (NMN) over an extended period. The supplement industry is not well-regulated, and there are concerns about the quality and consistency of NMN supplements. This can make it difficult for consumers to know which products are safe and effective.  

• Regulatory removal in the U.S.: In 2023, the U.S. FDA removed NMN from dietary supplement status, citing its potential overlap with drug investigation—hindering launch into mainstream retail channels

• Production cost impact: Per Global Info Research, Asia‑Pacific accounts for over 60% of NMN production, which helps maintain global price stability—but also highlights a reliance on regional manufacturing, limiting diversification

• Request a Free sample to learn more about this report

•  

BETA-NICOTINAMIDE MONONUCLEOTIDE (NMN) MARKET REGIONAL INSIGHTS

The North America Region will Dominate Market Due to Strong Demand for Anti-Aging Supplements

North America is the largest market for beta-nicotinamide mononucleotide (NMN), being the primary consumer. The region has a large aging population, which has increased interest in anti-aging supplements like NMN. The region is also home to many supplement companies, which have contributed to the availability of beta-nicotinamide mononucleotide (NMN) in the market.

Asia Pacific is expected to be the fastest-growing market for beta-nicotinamide mononucleotide (NMN). The region has a large aging population, and there is an increasing interest in anti-aging supplements. Additionally, there is a long history of using traditional medicines and supplements in the region, which has contributed to the popularity of beta-nicotinamide mononucleotide (NMN).  

KEY INDUSTRY PLAYERS

Adoption Aluminum Recycling Services by Key Players Influencing Market Development

The top key players in the market are GeneHarbor, Herbalmax, Genex Formulas, Shinkowa Pharmaceutical, Maac10 Formulas, EffePharm. Most of the top players hold the beta-nicotinamide mononucleotide (NMN) market shares. In addition, the strategies to develop new technologies, capital investment in R&D, improve product quality, acquisitions, mergers, and compete for the beta-nicotinamide mononucleotide (NMN) market growth in the competition help them to perpetuate their position and value in the market. Besides, collaboration with other companies & extensive possession of market shares by the key players stimulates the beta-nicotinamide mononucleotide (NMN) market.  

GeneHarbor: Identified as one of the top three global NMN providers, contributing to approximately 74% of total global NMN revenue in 2023.

Herbalmax: Ranked among the top five NMN manufacturers, with Asia‑Pacific output exceeding 60% of global supply.

List of Top Beta-Nicotinamide Mononucleotide (NMN) Companies

• GeneHarbor (China)
• Herbalmax (U.S.)
• Genex Formulas (U.S.)
• Shinkowa Pharmaceutical (Japan)
• Maac10 Formulas (U.S.)
• EffePharm (China)
• Bontac (U.S.)
• CELFULL (China)
• Kingdomway (China)

REPORT COVERAGE

This report examines an understanding of the beta-nicotinamide mononucleotide (NMN) market’s size, share, growth rate, segmentation by type, application, key players, and previous and current market scenarios. The report also collects the market’s precise data and forecasts by market experts. Also, it describes the study of this industry’s financial performance, investments, growth, innovation marks, and new product launches by the top companies and offers deep insights into the current market structure, competitive analysis based on key players, key driving forces, and restraints that affect the demand for growth, opportunities, and risks.

Furthermore, the post-COVID-19 pandemic’s effects on international market restrictions and a deep understanding of how the industry will recover, and strategies are also stated in the report. The competitive landscape has also been examined in detail to provide clarification of the competitive landscape.

This report also discloses the research based on methodologies that define price trend analysis of target companies, collection of data, statistics, target competitors, import-export, information, and previous years’ records based on market sales. Moreover, all the significant factors which influence the market such as small or medium business industry, macro-economic indicators, value chain analysis, and demand-side dynamics, with all the major business players have been explained in detail. This analysis is subject to modification if the key players and feasible analysis of market dynamics change.